Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) has secured a second U.S. patent allowance for its EVM401 Series, covering novel methylone-inspired compounds designed for mental health treatment. The patent, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," focuses on non-hallucinogenic benzodioxole derivatives engineered to modulate neurotransmitters for neuropsychiatric disorders.

The compounds are structurally similar to methylone, which has shown positive Phase 2 results in PTSD treatment, but feature unique chemical structures enabling patent protection and potential repeat-dose outpatient care. Unlike methylone, which lacks composition patent exclusivity, Enveric's molecules are fully patentable and proprietary. The company will conduct further preclinical testing to evaluate safety, pharmacokinetics, and effectiveness against PTSD.

Enveric Biosciences (NASDAQ: ENVB) announced positive preclinical results for its lead drug candidate EB-003 in a PTSD model. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior (p < 0.05) in fear-conditioned mice one hour after administration, matching the therapeutic effects of MDMA used as control.

The research, conducted by a third-party lab, utilized a well-established translational rodent model. CEO Joseph Tucker highlighted that current FDA-approved PTSD treatments (SSRIs) achieve only 20-30% full remission rates with delayed onset of benefits. EB-003, as a next-generation neuroplastogen, shows potential to enhance hippocampal neuroplasticity without causing hallucinations, potentially offering a breakthrough in PTSD treatment.

Enveric Biosciences (NASDAQ: ENVB) has announced new data revealing that its lead candidate EB-003 acts as an agonist of the serotonin receptor 5-HT1B, expanding its potential therapeutic applications. The compound demonstrated agonism of 5-HT1B with an EC50 of 110 nM, complementing its known partial agonist activity on the 5-HT2A receptor.

This discovery broadens EB-003's potential applications to include major depressive disorder, Parkinson's disease, migraines, and cluster headaches. The drug candidate is currently in preclinical development, with IND-enabling activities planned through 2025. Previous data had shown positive pharmacology, in vitro safety, and oral bioavailability, including therapeutically relevant brain exposure in rodent models.

Enveric Biosciences (NASDAQ: ENVB), a biotech company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, announced its participation in the BIO International Convention from June 16-19, 2025, in Boston. CEO Joseph Tucker, Ph.D., will engage in one-on-one meetings with registered investors and potential partners during the event, where he will present the company's business strategy, recent achievements, and upcoming milestones.

Enveric Biosciences (NASDAQ: ENVB) has received a USPTO Notice of Allowance for a patent application covering novel aminated tryptamine derivatives, marking a significant advancement in non-hallucinogenic psychedelic-inspired therapeutics. The compounds, designed through Enveric's proprietary platform, demonstrated minimal hallucinogenic effects in preclinical testing, showing low Head Twitch Response and reduced 5-HT2A receptor activation. These therapeutics are specifically designed for frequent, outpatient dosing, targeting conditions like depression, anxiety, PTSD, and cognitive impairment. The patent covers both molecular compositions and therapeutic applications, strengthening Enveric's position in developing next-generation neuroplastogenic treatments that align better with patient lifestyles and clinical workflows.

Enveric Biosciences (NASDAQ: ENVB) has secured a new U.S. patent (USPTO #12,187,679) covering novel molecules with potential applications in sleep and CNS disorders. The patent, titled "Hydroxylated Psilocybin Derivatives and Methods of Using," includes compounds that selectively bind to the melatonin MT1 receptor, which regulates circadian rhythm and sleep-wake cycles. The molecules were identified through Enveric's structure-activity screening efforts and show promise as MT1-selective agonists for sleep therapeutics. Some compounds demonstrate broader CNS receptor engagement, potentially enabling new therapeutic approaches for psychiatric and neurological conditions. The patent strengthens Enveric's drug discovery platform and validates its strategy in targeting the multi-billion-dollar sleep disorder market.

Enveric Biosciences (NASDAQ: ENVB) has announced positive preclinical results for its lead drug candidate EB-003 in treating severe chronic depression. The drug demonstrated statistically significant improvements in the Open Space Forced Swim Test, a preclinical mouse model. At an oral dose of 30 mg/kg, EB-003 significantly reduced depression-like behavior within 30 minutes, showing comparable effects to Imipramine, an approved antidepressant.

The study confirmed the efficacy of the 30 mg/kg dose and revealed no adverse locomotor effects. Additionally, a 22-day daily dosing trial showed no adverse behavioral, physiological, or neurological effects, supporting its safety for long-term use. EB-003 is part of Enveric's EVM301 Series, designed to stimulate synaptic plasticity without hallucinogenic effects.

Enveric Biosciences (NASDAQ: ENVB) has filed a new provisional patent application for a family of molecules showing potential in treating neurodegenerative diseases. The molecules enhance brain-derived neurotrophic factor (BDNF) activity and target the BDNF/TrKB pathway, which supports neuroprotection and adult neurogenesis.

Initial testing revealed promising results, including promotion of neuronal development in cell-based assays. A prototype molecule demonstrated favorable pharmaceutical and pharmacokinetic characteristics, including effective oral delivery, brain penetration, and rapid plasma clearance, without showing 5HT2B receptor activation that could indicate cardiovascular risks.

The discovery could expand Enveric's market potential, targeting an estimated 50 million people worldwide affected by neurodegenerative diseases, including 7 million in the United States.

Enveric Biosciences (NASDAQ: ENVB) reported its Q1 2025 financial results and corporate updates. The company highlighted progress in developing EB-003, a neuroplastogenic molecule for treating depression, anxiety, and addiction disorders, with plans to submit an IND application by Q1 2026. Key developments include: unveiling the EVM401 Series of mescaline derivative compounds, expanding IP protection for EB-003, and signing two licensing agreements for cannabinoid-COX-2 conjugate compounds targeting joint conditions. Financially, Enveric reported a net loss of $2.2 million ($1.22 per share) in Q1 2025, compared to $2.5 million loss in Q1 2024. The company closed a $5 million public offering and had $4.3 million cash on hand as of March 31, 2025.